HHSC will publish updates to the semi-annual Texas Medicaid Preferred Drug List (PDL) in two parts:
- The Texas Drug Utilization Review (DUR) Board reviewed the Hepatitis C drug class for PDL status at the Oct. 24, 2025, meeting. HHSC will implement that class's recommendations on Jan. 1, 2026.
- We will publish the remaining changes based on the recommendations from the July and Oct. 2025 DUR Board meetings on Jan. 30, 2026.
Refer to the Vendor Drug Program website for more information.
HHSC requires application fees for pharmacies enrolling with Medicaid. The fee for applications submitted in the calendar year 2026 will be $750.00. Refer to the
Vendor Drug Program website for more information.
An update to the
Clinical Prior Authorization Assistance Chart is available. The chart identifies the clinical prior authorizations each MCO uses and how those relate to those used for traditional Medicaid claim processing. Refer to the
Vendor Drug Program website for more information.
Human Respiratory Syncytial Virus (RSV) causes respiratory tract infections and severe lung disease in infants and children. Synagis (palivizumab) is available for children with a high risk of infection. The Texas Health and Human Services Commission will open the 2025-26 monthly prophylaxis for RSV on Oct. 1, 2025. Refer to the Vendor Drug Program website for more information.
